

CEO's presentation ahead of the 2021 Annual General Meeting has been published

Biovica, active in cancer diagnostics, today announced that a pre-recorded presentation with CEO Anders Rylander has been published.

The Annual General Meeting of Biovica International AB on 31 August 2021 will take place without physical presence, due to the risk of spreading Covid-19. Ahead of the AGM, a pre-recorded presentation with CEO Anders Rylander has been published today. In the presentation, Anders Rylander describes the past financial year and gives his view on the company's future development. The presentation is available on the company's website [Events – Biovica](#) and at [youtube](#).

Contact

Anders Rylander, CEO

Phone: +46-18-444 48 35

E-mail: anders.rylander@biovica.com

Biovica – Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

Attachments

[CEO's presentation ahead of the 2021 Annual General Meeting has been published](#)